Medical Marijuana - Medical, Legal, Social and Political Issues
You are not logged in. Only partial content from this topic will be available to you. To view the full content, you must log in to your account. Don't have a login? Register now. Or, check out our Preview.

The Medical Use of Cannabis and Cannabinoids in Parkinson's Disease


CB1 receptors are densely expressed in the basal ganglia and cortical areas affected in Parkinson's disease (Venderova et al., 2005, Brotchie et al., 2005). Because of this, there is a rationale for usage of THC in the disorder. Also, CBD has been assessed as a potential therapeutic agent for Parkinson’s disease because of its possible neuroprotective attributes (Fernandez-Ruiz et al., 2011). This module will review the available clinical evidence for the use of cannabis in the treatment of Parkinson’s disease and the associated symptoms of Parkinson's disease.



Take a quiz or play a crossword related to this syllabus topic.

This syllabus content additionally qualifies for the following CME designations: Medical Marijuana, Pain Medicine, Palliative Care, Risk Management